Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.62

Prime Medicine, Inc. Price to Earnings Ratio (P/E) is -1.62 on January 14, 2025, a 60.10% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Prime Medicine, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.58 on December 18, 2024, which is 2.22% above the current Price to Earnings Ratio (P/E).
Prime Medicine, Inc. 52-week low Price to Earnings Ratio (P/E) is -5.42 on February 27, 2024, which is -235.68% below the current Price to Earnings Ratio (P/E).
Prime Medicine, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.16.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years